市場調査レポート

世界の疼痛管理薬と機器の市場

The World Market for Pain Management Drugs and Devices

発行 Kalorama Information 商品コード 273155
出版日 ページ情報 英文 270 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.85円で換算しております。
Back to Top
世界の疼痛管理薬と機器の市場 The World Market for Pain Management Drugs and Devices
出版日: 2013年05月20日 ページ情報: 英文 270 Pages
概要

近年疼痛管理の分野ではさまざまな動きが出ており、臨床現場で利用可能な選択肢の幅も広がりつつあります。疼痛性障害に対する治療法を見つけ出すのは困難ですが、ヒトや動物についての継続的な研究を通じて疼痛に影響を及ぼす生化学的な要因や神経生理学的な要因が究明される可能性は高まっており、今後疼痛管理の現場では、各分野の専門医が共同で治療法の発見に取り組むことになると見られています。疼痛管理に対する世界的なニーズが高まるなか、治療薬のメーカーは、製品の差別化を図ることで価格競争を回避し、収益を伸ばそうとしていますが、課題も少なくありません。

当レポートは、世界の疼痛管理薬と機器の市場を詳細に分析し、今後の展望を示したもので、やけど、がん性疼痛、歯痛/顔面痛、頭痛、筋骨格痛、神経障害性疼痛、産婦人科、小児科、術後/外傷後疼痛の各分野に対応する疼痛治療薬と機器の市場の現状と今後の見通し、主な課題やトレンドなどを明らかにするとともに、主要企業各社のプロファイルも盛り込み、概略以下の構成でお届けします。

第1章 エグゼクティブサマリー

  • イントロダクション
  • 調査の範囲と方法
  • 市場の規模と成長性
  • 課題とトレンド
  • 競合関係にある主な企業

第2章 イントロダクションと概況

  • 疼痛の定義
  • 疼痛の程度
  • 疼痛の生理学
  • 疼痛伝達経路
  • 疼痛のタイプ
  • 疼痛の測定
  • 治療のモダリティ−薬理学的管理
  • 治療のモダリティ−非薬理学的管理

第3章 各種治療法の市場と予測

  • やけど
  • がん性疼痛
  • 歯痛/顔面痛
  • 偏頭痛
  • 筋骨格痛
  • 神経障害性疼痛
  • 産婦人科関連の疼痛
  • 小児科関連の疼痛
  • 術後および外傷後の疼痛

第4章 ドラッグデリバリー

  • 経口投与
  • 非経口投与
  • 経皮投与
  • 患者自己調節鎮痛法(PCA)
  • 髄腔内移植
  • エレクトロトランスポートドラッグデリバリー

第5章 疼痛管理機器

  • 経皮電気神経刺激
  • 神経筋刺激
  • 脊髄電気刺激と末梢神経刺激
  • PCAと髄腔内薬剤投与ポンプ
  • 他の機器
  • 市場規模と成長性

第6章 他の治療用モダリティ技術

  • 鍼治療
  • ETPS(Electro Therapeutic Point Stimulation)法による神経障害の鍼治療
  • 低レベルレーザー光治療
  • バイオフィードバック
  • リラクゼーション
  • 音楽と鎮痛
  • ウェーブ療法
  • 指圧療法
  • マッサージ療法
  • 疼痛管理における天然サプリメント
  • 生体電磁気学的療法
  • 高周波技術
  • 冷凍アブレーション

第7章 課題とトレンド

  • 概要
  • がん疼痛管理の障害
  • 教育
  • 慢性痛と作業
  • マネージドケアの疼痛管理
  • 5番目のバイタルサイン
  • 慢性痛における精神薬理学の活用
  • ボツリヌス神経毒素の利用
  • 研究と開発
  • 高齢者
  • オキシコンチンの問題
  • 恒常的な疼痛現象
  • タイレノールと肝臓障害
  • 鎮痛剤治療の混乱
  • トランスポーターの発見
  • マリファナと疼痛管理
  • 乱用抑止性鎮痛剤
  • 薬物乱用と疼痛管理

第8章 市場のサマリー

  • 市場全体の規模と予測
  • 各地域市場の売上高
  • 競合企業の分析

第9章 主要企業各社のプロファイル

  • Abbott Laboratories
  • Actavis, Inc (formerly Watson Pharmaceuticals, Inc.)
  • AstraZeneca plc.
  • Baxter International, Inc.
  • BioDelivery Sciences International (BDSI)
  • Boehringer Ingelheim
  • Boston Scientific
  • Bristol-Myers Squibb Company
  • DepoMed
  • DURECT Corporation
  • Eli Lilly & Co.
  • Endo Health Solutions Inc
  • GlaxoSmithKline plc
  • Grunenthal Group
  • Medtronic, Inc.
  • Merck & Co.
  • Novartis
  • Pain Therapeutics, Inc
  • Pfizer, Inc
  • Purdue Pharma
  • QRx Pharma
  • Sanofi
  • St. Jude Medical, Inc
  • TEVA Pharmaceuticals Industries, Ltd
  • The Medicines Company
  • Valeant Pharmaceuticals International, Inc.
  • Zogenix, Inc.

付録:企業要覧

図表

目次
Product Code: KLI5042319

Abstract

The World Market for Pain Management Drugs and Devices encompasses a wide variety of products that treat and ease pain. The field of pain management is currently experiencing a busy and interesting period; and as a result, the range of therapeutic options available to physicians and other clinicians has expanded. Solutions to pain disorders are still elusive but continued human and animal studies will help to further identify the biochemical and neurophysiological factors that influence pain. The future of pain management will likely involve multidisciplinary departments dedicated to finding treatments that manage pain. The need is great worldwide for management of pain and there are still many facets of pain management that need to be explored.

Faced with intensifying competition and increasingly price sensitive markets, manufacturers in the area of pain management therapeutics are trying to differentiate their products to avoid price competition and to increase profits. However, there are a number of issues and trends that have a direct influence on this market and the manufacturer's ability to successfully operate in the market. A keen awareness of all facets of the industry including barriers will enable manufacturers to effectively challenge these issues and formulate plans to reduce or eliminate barriers in the treatment of pain.

The driving forces for this market include growth and aging of the global population, new products and technology, and increasing interest in multidisciplinary approaches to pain management.

This report, The World Market for Pain Management Drugs and Devices, provides market estimates and forecasts for the following therapeutic categories:

  • Burn Pain
  • Cancer Pain
  • Dental/Facial Pain
  • Migraine Headache Pain
  • Musculoskeletal Pain
  • Neuropathic Pain
  • Obstetrical Pain
  • Pediatric Pain
  • Surgical and Trauma Pain

This report details the various categories of top prescription pain management drugs, describes U.S., European, Japanese and other markets in each of the specific pain areas. The report also covers drug delivery methods, pain management devices, and alternate treatment modalities that are influencing the market. It further identifies major market factors, which are discussed, and a total market summary is presented.

The information and analysis presented in this report are based on extensive interviews with senior management of top companies and conference participants (business and clinical) in the pain management market. Background information was obtained from a comprehensive search of published literature and reports obtained from various government, business, medical trade, and international journals. Key information from published literature was used to conduct interviews with over 45 industry executives and product managers to validate and obtain expert opinion on current and future trends in the pain management market. Interviews were also used to confirm and/or adjust market size estimates, as well as in formulating market projections.

All market data pertain to the world market at the manufacturers' level. Data are expressed in current U.S. dollars. The base year for data was 2012. Historical data is provided for 2010 and 2011, and forecast data are provided for each of the years 2012 through 2017. Historical, base year, and forecast data are provided for each market segment. Market shares are provided for each market segment for the 2012 base year.

Top product revenues are considered for the report in each subsegment according to treatment use. Top products in each category represent approximately 80% of the total revenues for each subsegment. The total market reflects the total revenues of all top products in all of the individual categories, representing approximately 80%-90% of the total prescription pain management pharmaceuticals and pain management devices.

As part of the study the following competitors are profiled:

  • Abbott Laboratories
  • Actavis, Inc (formerly Watson Pharmaceuticals, Inc.)
  • AstraZeneca plc.
  • Baxter International, Inc.
  • BioDelivery Sciences International (BDSI)
  • Boehringer Ingelheim
  • Boston Scientific
  • Bristol-Myers Squibb Company
  • DepoMed
  • DURECT Corporation
  • Eli Lilly & Co.
  • Endo Health Solutions Inc
  • GlaxoSmithKline plc
  • Grunenthal Group
  • Medtronic, Inc.
  • Merck & Co.
  • Novartis
  • Pain Therapeutics, Inc
  • Pfizer, Inc
  • Purdue Pharma
  • QRx Pharma
  • Sanofi
  • St. Jude Medical, Inc
  • TEVA Pharmaceuticals Industries, Ltd
  • The Medicines Company
  • Valeant Pharmaceuticals International, Inc.
  • Zogenix, Inc.

Table of Contents

CHAPTER ONE: EXECUTIVE SUMMARY

  • Introduction
  • Scope and Methodology
  • Size and Growth of the Market
  • Issues and trends
  • Leading Competitors

CHAPTER TWO: INTRODUCTION AND OVERVIEW

  • Definition of Pain
  • Magnitude of Pain
  • Physiology of Pain
    • Transduction
    • Transmission
  • Pain Pathways
  • Types of Pain
  • Measurement of Pain
  • Treatment Modalities-Pharmacologic Management
    • Analgesic Ladder
      • Step I Drugs
      • Step II Drugs
      • Step III Drugs
    • Recommended Drug and Route
      • Administration Routes
      • Titration
  • Treatment Modalities-Non-pharmacologic Management
    • Cognitive-Behavioral Therapies
    • Multidisciplinary Pain Management
    • Demographics

CHAPTER THREE: TREATMENT MARKETS AND FORECASTS

  • Burn Pain
    • Overview of Top Products
      • Opiate Agonists-Natural Alkaloids
      • Opiate Agonists-Semisynthetic Analogs
      • Opiate Agonists-Synthetic Compounds
    • Market Size and Growth
      • Markets by Region
    • Cancer Pain
      • Breakthrough Cancer Pain
      • Overview of Top Products
        • Opiate Agonists- Natural Alkaloids
        • Opiate Agonists-Semisynthetic Analogs
        • Opiate Agonists- Synthetic Compounds
        • Phenylpiperdine Compounds
        • New and/or Innovative Products
      • Market Size and Growth
      • Markets by Region
    • Dental/Facial Pain
      • Overview of Top Products
        • Opiate Agonists- Natural Alkaloids
        • Opiate Agonists-Semisynthetic Analogs
        • Opiate Agonists- Synthetic Compounds
        • Opiate Agonist-Antagonists
        • Centrally-acting Synthetic Analgesic Compounds
        • New Products
      • Market Size and Growth
      • Markets by Region
    • Migraine Headache Pain
      • Overview of Top Products
        • Selective Serotonin Agonists
        • New and/or Innovative Products
      • Market Size and Growth
      • Markets by Region
    • Musculoskeletal Pain
      • Overview of Top Products
        • Phenylpiperidine Compounds
        • Cox-2 Inhibitors
        • Non-steroid Anti-inflammatory Drugs
        • Opioid Agonists- Natural Alkaloids
        • Hyaluronate Sodium Derivative
        • New and/or Innovative Products
      • Market Size and Growth
      • Markets by Region
    • Neuropathic Pain
    • Overview of Top Products
      • Antiseizure Drugs
      • Opiate Agonists- Natural Alkaloids
      • Opiate Agonists-Semi-Synthetic Analogs
      • Phenylpiperidine Compounds
      • New and/or Innovative Products
    • Market Size and Growth
    • Markets by Region
  • Obstetrical Pain
    • Overview of Top Products
      • Opiate Agonists-Synthetic Compounds
      • Opiate Agonist-Antagonists
      • Centrally Acting Synthetic Analgesic Compounds
      • Phenylpiperidine Compounds
    • Market Size and Growth
    • Markets by Region
  • Pediatric Pain
    • Overview of Top Products
      • Opiate Agonist-Antagonists
      • Indole Analogs
      • Opiate Agonists-Semisynthetic Analogs
      • Opiate Agonists- Natural Alkaloids
    • Market Size and Growth
    • Markets by Region
  • Surgical and Trauma Pain
    • Overview of Top Products
      • Opiate Agonists-Natural Alkaloids
      • Opiate Agonists-Semisynthetic Analogs
      • Opiate Agonists-Synthetic Compounds
      • Opiate Agonist-Antagonists
      • Centrally Acting Synthetic Analgesic Compounds
      • New and/or Innovative Product Approvals
    • Market Size and Growth
    • Markets by Region

CHAPTER FOUR: DRUG DELIVERY

  • Oral Drug Delivery
  • Parenteral Drug Delivery
  • Transdermal
  • Patient Controlled Analgesia
  • Intrathecal Implants
  • Electrotransport Drug Delivery

CHAPTER FIVE: PAIN MANAGEMENT DEVICES

  • Transcutaneous Electrical Nerve Stimulators
  • Table of Contents v
  • Neuromuscular Stimulators
  • Spinal Cord Stimulators and Peripheral Nerve Stimulators
  • PCAs and Intrathecal Pain Pumps
  • Other Miscellaneous devices
    • Cranial Electrotherapy Stimulation
    • Electrothermal and Electromagnetic Therapy
    • Thermography
  • Market Size and Growth
    • Markets by Region

CHAPTER SIX: ALTERNATE TREATMENT MODALITIES

  • Acupuncture
  • ETPS Neuropathic Acupuncture
  • Low Level Laser Light Therapy
  • Biofeedback
  • Relaxation
  • Music and Pain Relief
  • Wave Therapy
  • Acupressure
  • Massage Therapy
  • Natural Supplements in Pain Management
  • Bioelectromagnetism
  • Radiofrequency Technology
  • Cryoablation

CHAPTER SEVEN: ISSUES AND TRENDS

  • Overview
  • Barriers to Cancer Pain Management
  • Education
  • Chronic Pain and Work
  • Managed Care Pain Management
  • The Fifth Vital Sign
  • Use of Psychopharmacology in Chronic Pain
  • Use of Botulinum Neurotoxin
  • Research and Development
  • Table of Contents vi
    • Dyloject
    • Levadex
    • MoxDuo IR
    • Naproxcinod
    • Pennsaid 2%
    • Posidur
    • Remoxy
    • Zelrix
    • Zohydro ER
    • ARC-4558
    • BEMA Buprenorphine
    • NGX 1998
    • Sativex
    • ATx08-001
  • The Elderly
  • Oxycontin Issues
  • Constant Pain Phenomenon
  • Tylenol and Liver Damage
  • Pain Medication Treatment Confusion
  • Transporter Discovery
  • Marijuana and Pain Control
  • Abuse-Deterrent Painkillers
  • Drug Abuse and Pain Control

CHAPTER EIGHT: MARKET SUMMARY

  • Total Market Size and Forecast
  • Total Market Revenues by Region
  • Competitor Analysis

CHAPTER NINE: CORPORATE PROFILES

  • Abbott Laboratories
  • Actavis, Inc (formerly Watson Pharmaceuticals, Inc.)
  • AstraZeneca plc.
  • Baxter International, Inc.
  • BioDelivery Sciences International (BDSI)
  • Boehringer Ingelheim
  • Boston Scientific
  • Table of Contents vii
  • Bristol-Myers Squibb Company
  • DepoMed
  • DURECT Corporation
  • Eli Lilly & Co.
  • Endo Health Solutions Inc
  • GlaxoSmithKline plc
  • Grunenthal Group
  • Medtronic, Inc.
  • Merck & Co.
  • Novartis
  • Pain Therapeutics, Inc
  • Pfizer, Inc
  • Purdue Pharma
  • QRx Pharma
  • Sanofi
  • St. Jude Medical, Inc
  • TEVA Pharmaceuticals Industries, Ltd
  • The Medicines Company
  • Valeant Pharmaceuticals International, Inc.
  • Zogenix, Inc.

APPENDIX: COMPANY DIRECTORY

LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY

  • Summary Table: Total World Pain Management Market 2010-2017
  • Summary Figure: Total World Pain Management Market 2010-2017

CHAPTER TWO: INTRODUCTION AND OVERVIEW

  • Table 2-1: Most Commonly Used Pain Quality Descriptors
  • Table 2-2: Pharmacokinetics of Step I Analgesics by Product
  • Table 2-3: Step II Analgesics: Pharmacokinetics
  • Table 2-4: Step III Analgesics: Pharmacokinetics
  • Table 2-5: Worldwide Prevalence of Selected Pain Related Conditions (est. 2012)

CHAPTER THREE: TREATMENT MARKETS AND FORECASTS

  • Table 3-1: World Market for Burn Pain Management 2010-2017
  • Table 3-2: Regional Markets for Burn Pain Management 20010-2017
  • Figure 3-2: Regional Markets for Burn Pain Management 2010-2017
  • Table 3-3: World Market for Cancer Pain Management 2010-2017
  • Figure 3-3: World Market for Cancer Pain Management 2010-2017
  • Table 3-4: Regional Markets for Musculoskeletal Pain Management 2010-2017
  • Figure 3-4: Regional Markets for Musculoskeletal Pain Management 2010-2017
  • Table 3-5: The World Market for Dental/Facial Pain Management 2010-2017
  • Figure 3-5: The World Market for Dental/Facial Pain Management 2010-2017
  • Table 3-6: Regional Markets for Dental/Facial Pain Management 2010-2017
  • Figure 3-6: Regional Markets for Dental/Facial Pain Management 2010-2017
  • Table 3-7: World Market for Migraine Pain Management 2010-2017
  • Figure 3-7: World Market for Migraine Pain Management 2010-2017
  • Table 3-8: Regional Markets for Migraine Pain Management 2010-2017
  • Figure 3-8: Regional Markets for Migraine Pain Management 2010-2017
  • Table 3-9: World Market for Musculoskeletal Pain Management 2010-2017
  • Figure 3-9: World Market for Musculoskeletal Pain Management 2010-2017
  • Table 3-10: Regional Markets for Musculoskeletal Pain Management 2010-2017
  • Figure 3-10: Regional Markets for Musculoskeletal Pain Management 2010-2017
  • Table 3-11: World Market for Neuropathic Pain Management 2010-2017
  • Figure 3-11: World Market for Neuropathic Pain Management 2010-2017
  • Table 3-12: Regional Markets for Neuropathic Pain Management 2010-2017
  • Figure 3-12: Regional Markets for Neuropathic Pain Management 2010-2017
  • Table 3-13: World Market for Obstetrical Pain Management 2010-2017
  • Figure 3-13: World Market for Obstetrical Pain Management 2010-2017
  • Table 3-14: Regional Markets for Obstetrical Pain Management 2010-2017
  • Figure 3-14: Regional Markets for Obstetrical Pain Management 2010-2017
  • Table 3-15: The World Market for Pediatric Pain Management 2010-2017
  • Table 3-16: Regional Markets for Pediatric Pain Management 2010-2017
  • Figure 3-16: Regional Markets for Pediatric Pain Management 2010-2017
  • Table 3-17: World Market for Surgical and Trauma Pain Management 2010-2017
  • Table 3-18: Regional Markets for Surgical and Trauma Pain Management 2010-2017
  • Figure 3-18: Regional Markets for Surgical and Trauma Pain Management 2010-2017

CHAPTER FIVE: PAIN MANAGEMENT DEVICES

  • Table 5-1: World Market for Pain Management Devices 2010-2017
  • Figure 5-1: World Market for Pain Management Devices 2010-2017
  • Table 5-2: Regional Markets for Pain Management Devices 2010-2017
  • Figure 5-2: Regional Markets for Pain Management Devices 2010-2017

CHAPTER SIX: ALTERNATE TREATMENT MODALITIES

  • Table 6-1: Pain Management Supplements in Clinical Trials

CHAPTER SEVEN: ISSUES AND TRENDS

  • Table 7-1: Pain Management Products in Development 2012

CHAPTER EIGHT: MARKET SUMMARY

  • Table 8-1: Total World Pain Management Market 2010-2017
  • Figure 8-1: Total World Pain Management Market 2010-2017
  • Table 8-2: World Pain Management Market by Product Segment (Pain Type), 2010-2017
  • Table 8-3: Total Regional Markets for Pain Management 2010-2017
  • Figure 8-4: Total Regional Markets for Pain Management 2010-2017
  • Table 8-4: World Market for Top Pain Management Treatments Revenues and Segments of Participation by Major Areas of Participation 2012
  • Table 8-5: Revenues and Market Share by Company 2012 (some are estimated)
  • Figure 8-6: Market Share Percent by Company 2012

CHAPTER NINE: CORPORATE PROFILES

  • Figure 9-1: Abbott's Financial Performance, 2010-2012
  • Figure 9-2: Actavis' Financial Performance, 2010-2012
  • Figure 9-3: AstraZeneca's Financial Performance, 2010-2012
  • Figure 9-4: Baxter International's Financial Performance, 2010-2012
  • Figure 9-6: Bristol-Myers Squibb's Financial Performance, 2010-2012
  • Figure 9-7: Eli Lilly's Financial Performance, 2010-2012
  • Figure 9-8: Endo Health Solutions' Financial Performance, 2010-2012
  • Figure 9-9: GlaxoSmithKline's Financial Performance, 2010-2012
  • Figure 9-10: Grunenthal's Financial Performance, 2010-2012
  • Figure 9-11: Johnson and Johnson's Financial Performance, 2010-2012
  • Figure 9-12: Medtronic's Financial Performance, 2010-2012
  • Figure 9-13: Merck's Financial Performance, 2010-2012
  • Figure 9-14: Novartis' Financial Performance, 2010-2012
  • Figure 9-15: Pfizer's Financial Performance, 2010-2012
  • Figure 9-16: Sanofi's Financial Performance, 2010-2012
  • Figure 9-17: St Jude's Financial Performance, 2010-2012
  • Figure 9-16: Teva's Financial Performance, 2010-2012
Back to Top